Comparative Pharmacology
Head-to-head clinical analysis: METHIMAZOLE versus THYROSHIELD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METHIMAZOLE versus THYROSHIELD.
METHIMAZOLE vs THYROSHIELD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits thyroid peroxidase, thereby blocking the synthesis of thyroid hormones (T3 and T4). Also inhibits peripheral conversion of T4 to T3.
Thyroshield (potassium iodide) acts by supplying excess iodide, which inhibits thyroid hormone synthesis via the Wolff-Chaikoff effect, blocks thyroidal iodide uptake, and reduces thyroid vascularity. It also protects the thyroid from radioactive iodine uptake by saturating iodine transport and organification mechanisms.
Oral, initial dose 15-40 mg daily in 3 divided doses; maintenance dose 5-15 mg daily
Intravenous: Loading dose 200 mg, then 50 mg every 6 hours; or continuous infusion: 200 mg bolus then 800 mg over 24 hours. Oral: 50 mg every 6 hours.
None Documented
None Documented
Clinical Note
moderateMethimazole + Prednisolone
"The serum concentration of Prednisolone can be decreased when it is combined with Methimazole."
Clinical Note
moderateMethimazole + Artesunate
"The serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Methimazole resulting in a loss in efficacy."
Clinical Note
moderateMethimazole + Fesoterodine
"The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Methimazole."
Clinical Note
moderate4-6 hours in euthyroid patients; prolonged to 10-15 hours in hyperthyroid patients. Clinical context: steady-state achieved in 2-3 days, but therapeutic effect on thyroid hormone synthesis requires 3-8 weeks due to depletion of stored hormones.
Terminal elimination half-life is 12-24 hours; clinical effect persists 24-36 hours after single dose.
Primarily renal (65-70% as unchanged drug and metabolites), with minor biliary/fecal elimination (<10%).
Primarily renal (90-95% unchanged), minor biliary/fecal (5-10%).
Category D/X
Category C
Antithyroid Agent
Antithyroid Agent
Methimazole + Clozapine
"The risk or severity of adverse effects can be increased when Methimazole is combined with Clozapine."